Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Administrative claims fund (1)
- Aggressive enforcement (1)
- Bribe (1)
- Burden of proof (1)
- Case review (1)
-
- Cheng (1)
- Civil defendants (1)
- Clinical Trial Participants (1)
- Cost-shifting (1)
- DOJ (1)
- Daubert (1)
- Declaratory judgment (1)
- Define foreign officials (1)
- Department of Justice (1)
- Difference in difference (1)
- Difference-in-difference (1)
- Drug (1)
- Empirical (1)
- Expert admissibility (1)
- Expert testimony (1)
- FCPA (1)
- FDA (1)
- FDAAA (1)
- First subscribers (1)
- Fixed effects (1)
- Fixed-effects (1)
- Food and Drug Administration (1)
- Foreign Corrupt Practices Act (1)
- Frye (1)
- Instrumentalities (1)
- Publication Type
Articles 1 - 4 of 4
Full-Text Articles in Law
Sacrificial Lambs: Compensating First Subscribers To Fda-Approved Medications For Postmarketing Injuries Resulting From Unlabeled Adverse Events, Rodney K. Miller
Sacrificial Lambs: Compensating First Subscribers To Fda-Approved Medications For Postmarketing Injuries Resulting From Unlabeled Adverse Events, Rodney K. Miller
Catholic University Law Review
No abstract provided.
The Stricter Standard: An Empirical Assessment Of Daubert’S Effect On Civil Defendants, Andrew Jurs, Scott Devito
The Stricter Standard: An Empirical Assessment Of Daubert’S Effect On Civil Defendants, Andrew Jurs, Scott Devito
Catholic University Law Review
No abstract provided.
Foreign Official Define Thyself: How To Define Foreign Officials And Instrumentalities In The Face Of Aggressive Enforcement Of The Foreign Corrupt Practices Act, Alexander L. Harisiadis
Foreign Official Define Thyself: How To Define Foreign Officials And Instrumentalities In The Face Of Aggressive Enforcement Of The Foreign Corrupt Practices Act, Alexander L. Harisiadis
Catholic University Law Review
No abstract provided.
“Reverse” Patent Declaratory Judgment Actions: A Proposed Solution For Medtronic, Megan M. La Belle
“Reverse” Patent Declaratory Judgment Actions: A Proposed Solution For Medtronic, Megan M. La Belle
Scholarly Articles
The United States Supreme Court is scheduled to hear arguments in Medtronic, Inc. v. Boston Scientific Corp. – the first patent case of the term – on November 5, 2013. The issue in Medtronic is whether the burden of proof in patent declaratory judgment actions should be on the patent owner to prove infringement or on the accused infringer to prove non-infringement. Ordinarily, the patent owner bears the burden of proving infringement and the declaratory posture of a suit does not shift that burden. In Medtronic, however, the Federal Circuit created an exception for “MedImmune-type” suits, meaning declaratory judgment actions …